Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Seres Therapeutics ( (MCRB) ) is now available.
On February 27, 2026, Seres Therapeutics’ board named director Richard N. Kender as Executive Chair and Interim CEO, effective March 2, 2026, while promoting Chief Scientific Officer Matthew Henn to President and Senior Vice President of Clinical Development Kelly Brady to Executive Vice President and Chief Operating Officer. Co-Presidents and Co-CEOs Thomas J. DesRosier and Marella Thorell stepped down from those roles on March 2 but remain as Chief Legal Officer and Chief Financial Officer, respectively, as part of a leadership reshuffle.
In connection with these changes, Seres approved new compensation and equity packages for Kender, Henn and Brady, including significant salary increases, retention or signing bonuses tied to continued service through December 31, 2026, and new stock option grants whose full vesting partly depends on shareholder approval of an expanded 2025 Incentive Award Plan. The enhanced pay, severance protections and equity awards underscore the board’s effort to stabilize and retain top leadership during an executive transition that may influence strategic direction and execution for investors and other stakeholders.
The most recent analyst rating on (MCRB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Seres Therapeutics stock, see the MCRB Stock Forecast page.
Spark’s Take on MCRB Stock
According to Spark, TipRanks’ AI Analyst, MCRB is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue base, ongoing operating losses, and sizable cash burn) and a soft technical setup (below key moving averages with negative MACD). Offsetting this, the latest earnings call was constructive on clinical progress and near-term catalysts, but the investment case remains meaningfully funding-dependent, with a limited stated cash runway.
To see Spark’s full report on MCRB stock, click here.
More about Seres Therapeutics
Seres Therapeutics, Inc. is a biotechnology company focused on developing microbiome-based therapeutics. The company operates in the biopharmaceutical industry, advancing drugs that modulate the human microbiome to treat serious diseases, positioning itself in a specialized segment of the healthcare market.
Average Trading Volume: 77,737
Technical Sentiment Signal: Strong Sell
Current Market Cap: $79.07M
For an in-depth examination of MCRB stock, go to TipRanks’ Overview page.